Syneron Announces Investor Meeting Focused on UltraShape U.S. Launch Update on September 17, 2014

Jul 25, 2014, 09:00 ET from Syneron Medical Ltd.

YOKNEAM, Israel, July 25, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.

The meeting will be hosted by Syneron's management team, including:

  • Shimon Eckhouse, Active Chairman of the Board
  • Amit Meridor, Chief Executive Officer
  • Hugo Goldman, Chief Financial Officer

The meeting will include presentations from physician guest speakers with direct experience with the UltraShape system and Syneron's products. The Company will issue an additional press release with further details regarding the event.

The investor meeting will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at Presentation slides accompanying the presentation will also be available through the Investor Relations section of Syneron's website. Please go to the website a few minutes early in order to download the presentation and as it may be necessary to download audio software to hear the presentation. The investor meeting webcast will be archived on the Investor Relations section on Syneron's website for six months following the event.

About Syneron Medical Ltd. Syneron Medical Ltd. (NASDAQ: ELOS) is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Logo -

SOURCE Syneron Medical Ltd.